消化指南

订阅

MedSci主页 / 所有栏目 / 消化指南

2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗

2023-09-30 国外肿瘤科相关专家小组（统称） Front Oncol 发表于上海

胆管癌

目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。

中文标题：

2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗

英文标题：

Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2023-09-30

简要介绍：

局部晚期或转移性胆管癌是一种预后差的侵袭性癌症。对于局部晚期或转移性胆管癌的一线治疗，顺铂/吉西他滨已作为标准治疗方案超过10年。目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=fafd51c0033a11bc, title=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗, enTitle=Systemic treatment of patients with locally advanced or metastatic cholangiocarcinoma - an Austrian expert consensus statement, guiderFrom= Front Oncol, authorId=0, author=, summary=目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。, cover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Sat Sep 30 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;"> <p>局部晚期或转移性胆管癌是一种预后差的侵袭性癌症。对于局部晚期或转移性胆管癌的一线治疗，顺铂/吉西他滨已作为标准治疗方案超过10年。目前，全身治疗治疗的领域正在扩大，本文主要针对局部晚期或转移性胆管癌患者的全身治疗提供共识指导。</p> </div> </div> <div class="detailsQRWrapper" style="color: #333333;"> <div id="app_detail" class="detailsQR" title="https://m.medlive.cn/guide/1/29820">&nbsp;</div> </div>, tagList=[TagDto(tagId=2872, tagName=胆管癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=2872, articleKeyword=胆管癌, articleKeywordNum=6, guiderKeywordId=2872, guiderKeyword=胆管癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5353, appHits=19, showAppHits=0, pcHits=419, showPcHits=5331, likes=1, shares=4, comments=4, approvalStatus=1, publishedTime=Mon Sep 18 14:50:00 CST 2023, publishedTimeString=2023-09-30, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=6, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Sep 18 12:12:40 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Fri Jan 05 01:03:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf)])
2023 奥地利专家共识声明：局部晚期或转移性胆管癌患者的全身治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-12-04 在风中 来自甘肃省

    值得学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-10-31 yixueyuan 来自江苏省

    认真学习，收获满满

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-10-31 1dea4a7em68(暂无匿称) 来自福建省

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2172927, encodeId=d70d21e2927ff, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eea21985113, createdName=在风中, createdTime=Mon Dec 04 21:16:18 CST 2023, time=2023-12-04, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=2165886, encodeId=961721658861a, content=认真学习，收获满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af092093304, createdName=yixueyuan, createdTime=Tue Oct 31 13:32:44 CST 2023, time=2023-10-31, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2165859, encodeId=99af216585927, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/23/914ab8c212b86139546fc16eed98b36f.jpg, createdBy=90821711402, createdName=1dea4a7em68(暂无匿称), createdTime=Tue Oct 31 10:36:05 CST 2023, time=2023-10-31, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2158304, encodeId=882d2158304a5, content=认真学习!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/52b37e2b3500d64012322279de0ea155/6701adcc53b818352061ec3cb03e7922.jpg, createdBy=5f871554375, createdName=54414749, createdTime=Mon Sep 18 15:57:15 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省)]
    2023-09-18 54414749 来自湖北省

    认真学习!

    0

相关指南

2022 AASLD实践指南：原发性硬化性胆管炎和胆管癌

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2023-02-02

胆管癌光动力治疗临床应用技术规范专家共识

中国医师协会外科医师分会胆道外科医师委员会 · 2023-03-27

胆管癌患者光动力治疗避光管理的最佳证据总结

广州医科大学附属第二医院肝胆外科一区 · 2022-12-10

2022 ESMO临床实践指南：胆管癌的诊断，治疗以及随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2022-11-03

2020 意大利临床实践指南：胆管癌-第1部分：分类，诊断和分期

意大利肝病学会(AISF,Italian Association for the Study of the Liver) · 2020-09-03

2016 ESMO临床诊疗指南：胆管癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

拓展阅读

JHO：从单细胞层面解析胆管癌的异质性及肝外胆管癌的特异性祖细胞微环境

本研究提供了 CCA 的综合单细胞图谱，揭示了 iCCA 和 eCCA 亚型之间的分子异质性，基于转录组的癌症细胞亚型划分对于临床分层和功能精准肿瘤学具有重要意义。

Cancer Cell：山东大学徐云飞等发现胆汁酸激活癌相关成纤维细胞并在胆管癌中诱导免疫抑制微环境

该研究发现过量的BA特异性激活癌症相关成纤维细胞上的GPBAR1以表达高水平的CXCL10，增强CCA细胞的上皮-间质转化和转移，并通过在CCA中募集中性粒细胞来创建免疫抑制肿瘤微环境。

European Radiology：磁共振成像和胆管造影对原发性硬化性胆管炎患者胆管癌的诊断效果评估

对于疑似 PSC 患者，磁共振（MR）成像和 MR 胆管造影是推荐的成像方式，也是 PSC 患者筛查 CCA 的标准方法。

主编新作 | J HEPATOL：线粒体形态调控——破解胆管癌顺铂耐药新策略

胆管癌发病率逐年上升，晚期患者顺铂联合吉西他滨治疗效果不佳。吉林大学第一医院等团队研究发现顺铂使胆管癌线粒体从分裂向超融合转变，揭示 INF2 降解机制，提出阻断 INF2 降解实现化疗增敏策略。

J Hepatol 吉林大学樊钟琦团队发现顺铂诱导的线粒体分裂体的破坏导致胆管癌对顺铂的耐药性增强！

该研究发现顺铂诱导的线粒体分裂体的破坏导致胆管癌对顺铂的耐药性增强。

Immunity：抗血管内皮生长因子治疗增强免疫检查点阻断疗法新机制

本研究深入探讨了抗VEGF治疗如何通过BAFF和IL-12依赖性机制增强ICB疗法在CCA中的抗肿瘤免疫反应。研究结果不仅揭示了VEGF抑制与ICB联合治疗的免疫学基础，还为临床应用提供了重要的参考。

2015 胆管癌诊断与治疗——外科专家共识

中华医学会外科学分会 · 2015-01-15

肝门部胆管癌规范化诊治专家共识（2015）

中国抗癌协会(Chinese Anti-cancer Association) · 2015-08-30

肝门部胆管癌诊断和治疗指南（2013版）的解读与思考

暂未更新 · 2016-06-08

AHPBA专家共识声明：肝内胆管癌（2015年）

美国肝胰胆协会(AHPBA,American Hepato-Pancreato-Biliary Association) · 2016-06-08

2016 ESMO临床诊疗指南：胆管癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

2020 意大利临床实践指南：胆管癌-第1部分：分类，诊断和分期

意大利肝病学会(AISF,Italian Association for the Study of the Liver) · 2020-09-03